Prostate Cancer Screening

Data Up to Date as of:

On This Page:

In 2021, 37.1% of men aged 55-69 years had a PSA test within the past year.

Summary graph for Prostate Cancer Screening, Click to see detailed view of graph

See Graph Details

Background

Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the level of PSA in a man’s blood. For this test, a blood sample is sent to a laboratory for analysis.

In 2012 the U.S. Preventive Services Task Force (USPSTF) recommended against prostate cancer screening. In May 2018, the USPSTF published a final recommendation statement to update PSA screening guidelines for two subsets of the population:

  1. for men age 70 years and older, the USPSTF recommends against PSA-based screening for prostate cancer, and
  2. for men ages 55 to 69 years, the USPSTF recommends that clinicians inform them about the potential benefits and harms of PSA-based screening for prostate cancer, stating that the decision about whether to be screened for prostate cancer should be an individual one.

Measure

The percentage of men aged 55 to 69 years who reported having had a PSA test within the past year, by race/ethnicity, income, education level, and age. This provides information about the use of PSA testing in the population. 

Measurement challenges

We track prostate cancer screening rates in U.S. using a large, national, in-person survey in which male respondents were asked several questions about prostate cancer and PSA testing, including whether they had ever had a PSA test and, if so, the time of their most recent test and the main reason for undergoing it (see Data Source, below). There are important limitations to this method that impact what information we can accurately collect and how confident we can be in the findings. Studies have found that certain types of healthcare survey questions can be difficult for people to clearly understand and answer, and it is easy for some questions to be misinterpreted.  

In the case of PSA screening, it may be challenging to determine by self-report alone if a PSA test was received for screening purposes, i.e., to look for asymptomatic, previously undetected cancer, or for diagnostic purposes, i.e., as a follow up on symptoms or suspicious findings from a prior test. Additionally, looking for new or recurrent asymptomatic cancer in a person previously diagnosed and treated for that cancer type represents a third type of testing known as surveillance testing. In some cases, because PSA testing is a blood test, it may be bundled by a clinician with other tests, and a man may be unaware he even had the test. Finally, men may also not always accurately recall the specific time they received a particular test. As such, our measure captures any type of PSA test received by a man, and the population may include those with a prior diagnosis of prostate cancer. This serves as a reasonable approximation, although an overestimate, of the true U.S. prostate cancer screening rate.

Even though the National Health Interview Survey prostate cancer screening measures have limitations, it is the best nationally representative data we have available to assess prostate cancer screening rates.

Healthy People 2030 Target

There is no Healthy People 2030 target related to being screened for prostate cancer. There is a target goal to increase the proportion of men who have discussed the advantages and disadvantages of the PSA test to screen for prostate cancer with their health care provider.

Healthy People 2030 is a set of goals set forth by the Department of Health and Human Services.

Note: Goals are indicated as blue line on Detailed Trend Graphs.

Data Source

Centers for Disease Control and Prevention, National Center for Health Statistics, National Health Interview Survey, 2005-2021.

In 2019 the NHIS questionnaire was redesigned to increase relevance, enhance data quality, and minimize respondent burden. In addition, the COVID-19 pandemic created challenges conducting in-person interviews for the 2020 NHIS, requiring changes to field procedures to conduct most surveys by telephone, which impacted survey response rates. For details related to the potential impacts of these issues, please refer to Potential Impact of NHIS Redesign and COVID-19 on the Cancer Trends Progress Report.

Trends and Most Recent EstimatesHelp with navigating the graphs and data tables

By Race/Ethnicity

Percent of men aged 55-69 years who had a prostate-specific antigen (PSA) test within the past year by race/ethnicity, 2005-2021
Overview Graph Detailed Trend Graphs Most Recent Estimates (2021)
Percent of adults 95% Confidence Interval
Thumbnail of graph for Percent of men aged 55-69 years who had a prostate-specific antigen (PSA) test within the past year by race/ethnicity, 2005-2021 All Races/EthnicitiesClick to see the detailed trend graph for All Races/Ethnicities 37.1 35.1 - 39.1
Non-Hispanic WhiteClick to see the detailed trend graph for Non-Hispanic White 40.7 38.5 - 42.9
Non-Hispanic BlackClick to see the detailed trend graph for Non-Hispanic Black 32.7 27.0 - 38.9
HispanicClick to see the detailed trend graph for Hispanic 29.1 23.0 - 36.1

By Poverty Income Level

Percent of men aged 55-69 years who had a prostate-specific antigen (PSA) test within the past year by poverty income level, 2005-2021
Overview Graph Detailed Trend Graphs Most Recent Estimates (2021)
Percent of adults 95% Confidence Interval
Thumbnail of graph for Percent of men aged 55-69 years who had a prostate-specific antigen (PSA) test within the past year by poverty income level, 2005-2021 <200% of federal poverty levelClick to see the detailed trend graph for <200% of federal poverty level 22.7 19.3 - 26.4
>=200% of federal poverty levelClick to see the detailed trend graph for >=200% of federal poverty level 41.0 38.7 - 43.3

By Education Level

Percent of men aged 55-69 years who had a prostate-specific antigen (PSA) test within the past year by highest level of education obtained, 2005-2021
Overview Graph Detailed Trend Graphs Most Recent Estimates (2021)
Percent of adults 95% Confidence Interval
Thumbnail of graph for Percent of men aged 55-69 years who had a prostate-specific antigen (PSA) test within the past year by highest level of education obtained, 2005-2021 Less than High SchoolClick to see the detailed trend graph for Less than High School 21.7 16.8 - 27.5
High SchoolClick to see the detailed trend graph for High School 35.8 32.1 - 39.6
Greater than High SchoolClick to see the detailed trend graph for Greater than High School 40.3 38.0 - 42.8

By Age

Percent of men aged 40 years and older who had a prostate-specific antigen (PSA) test within the past year by age at time of screening, 2005-2021
Overview Graph Detailed Trend Graphs Most Recent Estimates (2021)
Percent of adults 95% Confidence Interval
Thumbnail of graph for Percent of men aged 40 years and older who had a prostate-specific antigen (PSA) test within the past year by age at time of screening, 2005-2021 Ages 40-54Click to see the detailed trend graph for Ages 40-54 10.5 9.4 - 11.8
Ages 55-69Click to see the detailed trend graph for Ages 55-69 37.1 35.1 - 39.1
Ages 70+Click to see the detailed trend graph for Ages 70+ 48.8 46.4 - 51.1

Additional Information on Prostate Cancer Screening

Year Range

2005-2021

Recent Summary Trend Year Range

2019-2021

Summary Tables

Breast and Cervical Cancers

Recent Summary Trend

Falling

Desired Direction

Rising